OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

1 Projects | 1 Researchers | $873,830 Invested

2024

neotiv GmbH

David Berron, PhD

Integration of the neotiv digital cognitive assessments in the Swedish REAL AD study to screen and monitor preclinical Alzheimer’s disease

  • Funding Amount: $873,830
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Status: Active